Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Questions over AstraZeneca's COVID-19 vaccine data

11/26/2020 | 06:32pm EST

AstraZeneca is working with regulators to investigate a lower dosage of its experimental COVID-19 vaccine that performed better than a full dosage.

That's according to a spokesman for the company, who made the statement after its CEO was quoted as saying an additional global trial was likely - instead of adding the trial to an ongoing U.S. process.

Asked about a Bloomberg report which quoted CEO Pascal Soriot, an AstraZeneca spokesman said : "As we communicated earlier this week, there is strong merit in continuing to further investigate the half-dose/full dose regimen."

News of a likely additional trial comes as AstraZeneca faces questions about its success rate that some experts say could harm its chances of getting speedy U.S. and EU approval.

Several scientists have cast doubts on results released Monday showing the experimental vaccine was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.

AstraZeneca told Reuters earlier on Thursday that administering of the half dose had been reviewed and approved by independent monitors and the UK regulator.

Clearance from the U.S. Food and Drug Administration may take longer though because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, according to Soriot, especially given the questions over the results.


© Reuters 2020
All news about ASTRAZENECA PLC
10:11aASTRAZENECA : Italy to take legal action over COVID vaccine delays to get promis..
RE
09:00aASTRAZENECA : Italy to take legal action over COVID vaccine delays to secure dos..
RE
06:45aPFIZER : UK vaccination drive expands as virus toll nears 100,000
AQ
05:24aASTRAZENECA : EU says it will make vaccine companies respect supply contracts - ..
RE
03:21aASTRAZENECA : India to give homegrown vaccine in seven more states this week
RE
01/23THE LATEST : Chicago opens restaurants, some bars with limits
AQ
01/23UK vaccine roll-out speeds up but doctors want quicker second dose
RE
01/23AstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
DJ
01/23PFIZER : UK doctors seek review of 12-week gap between vaccine doses
AQ
01/23Italy PM says vaccine supply delays are serious contract violations
RE
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.19%139 483
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159